This week in MedTech, AI-driven care platforms, surgical innovation, and breakthrough drug-delivery technologies captured the spotlight. Strategic acquisitions, growth financings, and international expansion moves are accelerating the reach of digital health, advanced imaging, and clinical knowledge solutions worldwide. Read more below.
Sword Health agreed to acquire Kaia Health in a $285M deal
The acquisition reinforces Sword’s position as the fastest-growing AI Care platform in the world, expanding its ability to deliver high-quality, scalable care to new populations in the US while entering the German market.
Following the acquisition, Sword Health will replace Kaia’s MSK solution in the U.S. market, ensuring a seamless transition for existing clients and members.
Founder and CEO of Sword Virgilio Bento
CEO of Kaia Health Adam Pellegrini
Last week’s tracker: Oviva, LivsMed & more
Recare closed a €37M funding round to scale AI platform and expand internationally
The Berlin-based provider of technology solutions for hospitals and care providers closed a growth financing round of up to €37M, including a €7M option, to scale its AI platform and expand its international business.
The round was led by DNV, the independent assurance and risk management provider, with participation from CIBC Innovation Banking and other investors. This makes DNV the largest shareholder in Recare.
CEO Maximilian Greschke
CraniUS closed a $20M financing to support blood-brain barrier tech for drug delivery
The Series B round follows a $20M Series A round in 2022. CraniUS said its latest funding includes $19M from private investors, plus $1M in non-dilutive funding from the State of Maryland.
The company expects the new capital to support operations into 2027. It also expects it to go toward regulatory submissions, manufacturing scale-up and product testing toward future commercialization.
Founder Chad Gordon
EIB provided €20M in financing to SamanTree Medical
The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures.
The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372B in additional investment from 2021 to 2027.
CEO Olivier Delporte
Eolas Medical announced a $12M Series A to transform access to clinical knowledge worldwide
The Series A funding enables Eolas Medical to accelerate the development and global scale of its AI powered clinical knowledge platform.
The round was led by Munich based Acton Capital, with investment from Whiterock Capital, Portfolio Ventures, ScaleX Investments, Kindred Capital, Samaipata, and Ascension
Founder and CEO Declan Kelly
Nami Surgical completed latest investment round and named new CEO
Nami recently completed its latest investment, a £1.9M round led by Eos Advisory with participation from the Investment Fund for Scotland managed by Maven Capital Partners (and delivered by the British Business Bank), and Scottish Enterprise.
As CEO, Nikki Palfrey will lead Nami’s commercial strategy and partner engagement as the company progresses towards market entry.
CEO Nikki Palfrey
Turbett Surgical announced growth investment by J.P. Morgan Life Sciences Private Capital
Proceeds from the financing will provide working capital to fuel further product innovation and help the company scale its commercial team to meet overwhelming customer demand for the Instrument Pod solution.
This partnership underscores J.P. Morgan’s commitment to partnering with founders and founder-owned businesses, providing the strategic capital and support needed to empower innovative companies to scale and realize their full potential.
Co-Founder Robert Turbett
